Experts provide their perspectives on the evolving treatment landscape for patients with follicular lymphoma.
Current and Emerging Treatments in Follicular Lymphoma
Although the majority of patients with follicular lymphoma have a life expectancy similar to that of the general population, predicting which patients will relapse and finding therapies that provide durable responses in the relapsed or refractory setting remains an ongoing challenge.
Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.
Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.
Alan P. Z. Skarbnik, MD, discusses the watch-and-wait approach in patients with follicular lymphoma.
John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.
Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5